# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!


Extrahepatic bile duct cancer

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 31-40 of 50 results.
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Status: Recruiting
Last Changed: Mar 13, 2019
First Received: Jul 26, 2018
Disease(s): HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
Intervention(s): A166
Locations: Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
Beth Israel Deaconess Medical Center Cancer Center, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Clinical Research Alliance, Inc., Lake Success, New York, United States
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
... and 6 other locations.
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Status: Recruiting
Last Changed: Jan 22, 2020
First Received: Feb 20, 2017
Disease(s): Melanoma, Head and Neck Cancer, Lymphoma, Breast Cancer, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Ovarian Cancer, Sarcoma, Squamous Cell Carcinoma
Intervention(s): INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
Locations: USC Norris, Los Angeles, California, United States
USC HOAG, Newport Beach, California, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
UMASS Memorial Medical Center, Worcester, Massachusetts, United States
Columbia University Medical Center, New York, New York, United States
... and 3 other locations.
Integrated Cancer Repository for Cancer Research
Status: Recruiting
Last Changed: Oct 10, 2019
First Received: Dec 16, 2013
Disease(s): Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, GIST, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, CNS Tumor, CNS Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Locations: Penrose Cancer Center, Colorado Springs, Colorado, United States
Porter Adventist Hospital, Denver, Colorado, United States
St. Anthony Hospital, Lakewood, Colorado, United States
Parker Adventist Hospital, Parker, Colorado, United States
St. Mary Corwin Medical Center, Pueblo, Colorado, United States
... and 71 other locations.
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Status: Recruiting
Last Changed: Feb 24, 2020
First Received: May 01, 2014
Disease(s): Cholangiocarcinoma
Intervention(s): CX-4945, Cisplatin, Gemcitabine
Locations: Mayo Clinic, Scottsdale, Arizona, United States
University of Colorado- Denver, Aurora, Colorado, United States
Mayo Clinic, Jacksonville, Florida, United States
Mayo Clinic, Rochester, Minnesota, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
... and 12 other locations.
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
Status: Available
Last Changed: Jan 02, 2020
First Received: Jan 30, 2018
Disease(s): Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
Intervention(s): ABC294640
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma
Status: Recruiting
Last Changed: Jan 27, 2020
First Received: Dec 19, 2017
Disease(s): Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
Intervention(s): ABC294640, Hydroxychloroquine Sulfate 200 MG
Locations: Mayo Clinic Cancer Center, Phoenix, Arizona, United States
Emory University, Atlanta, Georgia, United States
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
MD Anderson Cancer Center, Houston, Texas, United States
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
... and 1 other locations.
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Status: Recruiting
Last Changed: Oct 10, 2019
First Received: Jul 27, 2018
Disease(s): Cholangiocarcinoma
Intervention(s): mFOLFOXIRI
Locations: Jarin Chindaprasirt, Khon Kaen, Thailand
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Status: Recruiting
Last Changed: Feb 10, 2020
First Received: Jul 26, 2019
Disease(s): Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
Intervention(s): LMB-100, Tofacitinib, Mesothelin Expression
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland, United States
EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice
Status: Recruiting
Last Changed: Jul 24, 2019
First Received: Apr 11, 2018
Disease(s): Pancreatic Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Ampulla of Vater Cancer, Jaundice, Obstructive
Intervention(s): Endoscopic ultrasound
Locations: Gastroenterology Department, Clinical Hospital Colentina, Bucharest, Romania
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Status: Recruiting
Last Changed: Jan 23, 2020
First Received: Jan 23, 2020
Disease(s): Intrahepatic Cholangiocarcinoma
Intervention(s): Durvalumab, Tremelimumab
Locations: Hannover Medical School, Hannover, Niedersachsen, Germany